Epitalon vs SS-31
Both Epitalon and SS-31 are used for longevity. Here's how their evidence, dosing, and regulatory status actually compare.
Epitalon
Evidence C+Epitalon (Epithalon, AEDG)
A synthetic tetrapeptide that reportedly upregulates telomerase activity. Russian longevity studies suggest mortality reductions but Western RCTs are absent.
View full Epitalon profile →SS-31
Evidence B+Elamipretide (SS-31)
A cell-permeable tetrapeptide that targets cardiolipin in the inner mitochondrial membrane. Investigated for primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration.
View full SS-31 profile →Side-by-Side
| Attribute | Epitalon | SS-31 |
|---|---|---|
| Evidence Grade | C+ | B+ |
| FDA Status | Not FDA-approved — Russian-origin research peptide | Not FDA-approved — Phase 3 trials for primary mitochondrial myopathy |
| Typical Dose | 5–10 mg daily for 10–20 days, cycled (subcutaneous) | Trial range: 40 mg subcutaneous daily |
| Clinics Indexed | 47 | 29 |
| Categories | anti-aging, longevity | mitochondrial, longevity |
Key reported benefits — Epitalon
- ✓Telomerase upregulation (preclinical)
- ✓Sleep/circadian normalization
- ✓Anti-aging signals
Key reported benefits — SS-31
- ✓Mitochondrial cardiolipin support
- ✓ATP production
- ✓Reduced oxidative damage
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.